| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CDK7 (cyclin-dependent kinase 7); inhibition blocks RNA polymerase II CTD phosphorylation and transcriptional elongation, suppressing oncogene expression and inducing apoptosis in CDK7-dependent cancer cells.
|
|---|---|
| ln Vitro |
Compound I (CDK7-IN-4) had IC50 values of 0.01419, 0,02312, 0.02553, 0.02651, and, respectively, 0.03201, 0.04601, and 0.0479, indicating strong inhibitory activity against NCI-H446, SNU-16, HCC1806, A2780, MCF7, HCT116, and NCI-H460 cells[1].
CDK7 IC50 = 92.8 nM; antiproliferative IC50 values: NCI-H446 0.01419 μM; SNU-16 0.02312 μM; HCC1806 0.02553 μM; A2780 0.02651 μM; MCF7 0.03201 μM; HCT116 0.04601 μM; NCI-H460 0.0479 μM; the compound is a potent, orally active CDK7 inhibitor with broad anticancer activity. |
| ln Vivo |
No dedicated in vivo efficacy data are summarized in the retrieved sources; the compound is orally active and shows potent antiproliferative activity, and animal-model validation with defined doses and tumor endpoints has not been detailed.
|
| Enzyme Assay |
CDK7 kinase assay: incubate recombinant CDK7/cyclin H/MAT1 with ATP and a CTD peptide substrate in the presence of serial dilutions, quantify phosphorylation by ADP-Glo or immunoblot, and calculate IC50 (92.8 nM); selectivity against CDK1, CDK2, CDK9 and other kinases is confirmed.
|
| Cell Assay |
Cellular transcription/apoptosis assay: treat CDK7-dependent cancer cells with serial dilutions (0.001–1 μM) for 24–72 h, measure viability by MTT (IC50 0.014–0.048 μM), and immunoblot pCDK7 (Ser164), pRNAPII CTD and c-Myc/Mcl-1; apoptosis is assessed by caspase-3 activity.
|
| Animal Protocol |
Xenograft protocol: implant NCI-H446 or HCC1806 cells subcutaneously in immunodeficient mice, randomize at ~100–150 mm³, administer CDK7-IN-4 orally at doses from a pilot PK/tolerability study, and monitor tumor growth plus pCDK7/pRNAPII pharmacodynamics.
|
| References |
| Molecular Formula |
C26H39N7O3
|
|---|---|
| Molecular Weight |
497.632965326309
|
| Exact Mass |
497.311
|
| CAS # |
2326428-25-3
|
| Related CAS # |
CDK7-IN-2;2326428-19-5
|
| PubChem CID |
138608764
|
| Appearance |
White to off-white solid
|
| LogP |
2.6
|
| tPSA |
95.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
36
|
| Complexity |
784
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NC2=C(C=NN2C(=C1)NC3CCN(CC3)C(=O)OC4CCN(C4)C(=O)/C=C/CN(C)C)C(C)C
|
| InChi Key |
GRDAHPJRLCTJNA-VOTSOKGWSA-N
|
| InChi Code |
InChI=1S/C26H39N7O3/c1-18(2)22-16-27-33-23(15-19(3)28-25(22)33)29-20-8-12-31(13-9-20)26(35)36-21-10-14-32(17-21)24(34)7-6-11-30(4)5/h6-7,15-16,18,20-21,29H,8-14,17H2,1-5H3/b7-6+
|
| Chemical Name |
[1-[(E)-4-(dimethylamino)but-2-enoyl]pyrrolidin-3-yl] 4-[(5-methyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-7-yl)amino]piperidine-1-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~251.2 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0095 mL | 10.0476 mL | 20.0953 mL | |
| 5 mM | 0.4019 mL | 2.0095 mL | 4.0191 mL | |
| 10 mM | 0.2010 mL | 1.0048 mL | 2.0095 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT03770494
Conditions:Solid Tumor